再発または難治性多発性骨髄腫の参加者におけるテクリスタマブとダラツムマブの皮下投与 (SC) (Tec-Dara) 対ダラツムマブ SC、ポマリドマイド、およびデキサメタゾン (DPd) またはダラツムマブ SC、ボルテゾミブ、およびデキサメタゾン (DVd) の研究 (MajesTEC-3)
再発または難治性多発性骨髄腫の参加者を対象に、ダラツムマブ SC (Tec-Dara) とダラツムマブ SC、ポマリドマイド、およびデキサメタゾン (DPd) またはダラツムマブ SC、ボルテゾミブ、およびデキサメタゾン (DVd) を組み合わせたテクリスタマブを比較する第 3 相ランダム化試験
The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 3
アクセスの拡大
アクセスの拡大
承認済み
- 利用可能: 現在、この治験治療には拡張アクセスが利用可能であり、臨床研究の参加者ではない患者が医薬品、生物学的製剤、または医療機器にアクセスできる可能性があります
- 利用不可: 以前はこの介入に対して拡張アクセスが利用できましたが、現在は利用できず、将来も利用できなくなります。
- 一時的に利用不可: 現在、この介入では拡張アクセスを利用できませんが、将来利用できるようになる予定です。
- マーケティング承認済み: 介入は、米国食品医薬品局によって一般使用が承認されています。
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35294
- University of Alabama Birmingham
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope
-
Stanford、California、アメリカ、94305-5623
- Stanford University Medical Center
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- Yale University
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- Emory University Winship Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02111
- Tufts Medical Center
-
-
Michigan
-
Detroit、Michigan、アメリカ、48202
- Henry Ford Hospital
-
Southfield、Michigan、アメリカ、48075
- Henry Ford Health System
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15224
- West Penn Hospital
-
Pittsburgh、Pennsylvania、アメリカ、15232
- University of Pittsburgh Medical Center
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425-8900
- Medical University of South Carolina
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38120
- Baptist Cancer Center
-
Nashville、Tennessee、アメリカ、37232
- Vanderbilt Ingram Cancer Center
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- University of Texas Southwestern Medical Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center
-
-
-
-
-
Buenos Aires、アルゼンチン、C1199ABB
- Hospital Italiano de Buenos Aires
-
CABA、アルゼンチン、C1118AAT
- Hospital Aleman
-
Córdoba、アルゼンチン、X5016KEH
- Hospital Privado Centro Medico de Cordoba
-
-
-
-
-
Blackpool、イギリス、FY3 8NR
- Blackpool Teaching Hospitals NHS Foundation Trust
-
Dundee、イギリス、DD1 9SY
- Ninewells Hospital & Medical School
-
London、イギリス、SE5 9RS
- Kings College Hospital
-
Oxford、イギリス、OX3 7LE
- Oxford University Hospitals NHS Foundation Trust
-
Plymouth、イギリス、PL6 8DH
- University Hospitals Plymouth NHS Trust
-
Sutton、イギリス、SM2 5PT
- Royal Marsden Hospital
-
-
-
-
-
Bari、イタリア、70124
- U.O. Ematologia con Trapianto- AOU Policlinico di Bari
-
Bergamo、イタリア、24127
- ASST Papa Giovanni XXIII Bergamo
-
Bologna、イタリア、40138
- Policlinico Sant'Orsola Malpighi
-
Florence、イタリア、50134
- Azienda Ospedaliera Universitaria Careggi
-
Meldola、イタリア、47014
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
-
Pavia、イタリア、27100
- IRCCS Policlinico San Matteo, Università degli studi di Pavi
-
Roma、イタリア、00161
- Università di Roma 'La Sapienza' - Ospedale Umberto 1°
-
Turin、イタリア、10126
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
-
-
-
-
Amsterdam、オランダ、1081 HV
- VU Medisch Centrum
-
Groningen、オランダ、9713 GZ
- Universitair Medisch Centrum Groningen
-
Nieuwegein、オランダ、3435 CM
- Sint Antonius Ziekenhuis - Afd.Interne - INT
-
Nijmegen、オランダ、6525GA
- Radboudumc
-
Zwolle、オランダ、8025 AB
- Isala Kliniek
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
Edmonton、Alberta、カナダ、T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V5Z 4E6
- BC Cancer Agency - Vancouver BC
-
-
Nova Scotia
-
Halifax、Nova Scotia、カナダ、B3H 2Y9
- QEII Health Sciences
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X6
- Princess Margaret Cancer Centre University Health Network
-
-
-
-
-
Athens Attica、ギリシャ、115 28
- Alexandra General Hospital of Athens
-
Thessaloniki、ギリシャ、57010
- G.Papanikolaou
-
Thessaloniki、ギリシャ、546 39
- Anticancer Hospital of Thessaloniki Theageneio
-
-
-
-
-
Falun、スウェーデン、791 82
- Falu Lasarett
-
Gothenburg、スウェーデン、413 45
- Sahlgrenska University Hospital
-
Helsingborg、スウェーデン、25187
- Helsingborgs lasarett
-
Luleå、スウェーデン、971 80
- Sunderby Sjukhus
-
Lund、スウェーデン、221 85
- Skanes universitetssjukhus
-
Umeå、スウェーデン、901 85
- Norrlands Universitetssjukhus
-
Uppsala、スウェーデン、75185
- Akademiska Sjukhuset
-
-
-
-
-
Barcelona、スペイン、08908
- Inst. Cat. Doncologia-H Duran I Reynals
-
Barcelona、スペイン、8035
- Hosp Univ Vall D Hebron
-
Gijón、スペイン、33394
- Hosp. de Cabuenes
-
Las Palmas de Gran Canaria、スペイン、35010
- Hosp. Univ. de Gran Canaria Dr. Negrin
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid、スペイン、28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Palma、スペイン、7120
- Hosp. Univ. Son Espases
-
Pamplona、スペイン、31008
- Clinica Univ. de Navarra
-
Pozuelo de Alarcón、スペイン、28223
- Hosp. Quiron Madrid Pozuelo
-
Salamanca、スペイン、37007
- Hosp Clinico Univ de Salamanca
-
Santander、スペイン、39008
- Hosp. Univ. Marques de Valdecilla
-
Santiago de Compostela、スペイン、15706
- Hosp. Clinico Univ. de Santiago
-
Seville、スペイン、41013
- Hosp. Virgen Del Rocio
-
Valencia、スペイン、46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Aalborg、デンマーク、DK-9000
- Aalborg University Hospital
-
Aarhus N、デンマーク、DK-8200
- Aarhus University Hospital
-
Copenhagen、デンマーク、2100
- Rigshospitalet
-
Odense、デンマーク、5000
- Odense Universitets Hospital
-
Vejle、デンマーク、DK-7100
- Vejle Hospital
-
-
-
-
-
Ankara、トルコ(Türkiye)、06590
- Ankara University Medical Faculty
-
Atakum、トルコ(Türkiye)、55280
- Ondokuz Mayis University
-
Istanbul、トルコ(Türkiye)、34214
- Medipol University Hospital
-
Izmir、トルコ(Türkiye)、35340
- Dokuz Eylul University Medical Faculty
-
-
-
-
-
Dresden、ドイツ、01307
- Universitaetsklinikum Carl-Gustav-Carus Dresden
-
Düsseldorf、ドイツ、40225
- Heinrich-Heine -Universitaet Duesseldorf
-
Essen、ドイツ、45239
- Evang. Krankenhaus Essen-Mitte gGmbH
-
Freiburg im Breisgau、ドイツ、79106
- Universitatsklinikum Freiburg
-
Hamburg、ドイツ、20246
- Universitaetsklinikum Hamburg Eppendorf
-
Hamm、ドイツ、59073
- St. Barbara-Klinik Hamm GmbH
-
Heidelberg、ドイツ、69120
- Universitaetsklinikum Heidelberg
-
Kiel、ドイツ、24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
Leipzig、ドイツ、04103
- Universitaetsklinikum Leipzig
-
Tübingen、ドイツ、72076
- Universitaetsklinikum Tuebingen
-
-
-
-
-
Créteil、フランス、94000
- CHU Henri Mondor
-
Lille、フランス、59000
- Hopital Claude Huriez
-
Limoges、フランス、87042
- CHU de Limoges Hopital Dupuytren
-
Lyon、フランス、69002
- Hospices Civils de Lyon HCL
-
Nantes、フランス、44093
- C.H.U. Hotel Dieu - France
-
Poitiers、フランス、86021
- CHU De Poitiers
-
Strasbourg、フランス、67200
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
-
Toulouse、フランス、31059
- Pôle IUC Oncopole CHU
-
Tours、フランス、37044
- CHRU Hôpital Bretonneau
-
-
-
-
-
Brasília、ブラジル、70390-140
- Hospitais Integradaos da Gavea S/A - DF Star
-
Curitiba、ブラジル、81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Florianópolis、ブラジル、88034-000
- Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
-
Natal、ブラジル、59062 000
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、ブラジル、90050-170
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Rio de Janeiro、ブラジル、22775 001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador、ブラジル、41253-190
- IDOR - Regional Bahia
-
São Paulo、ブラジル、4501000
- Instituto D Or de Pesquisa e Ensino IDOR
-
São Paulo、ブラジル、01323-000
- Hospital Paulistano
-
São Paulo、ブラジル、01323 900
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
São Paulo、ブラジル、04537 081
- Clinica Medica Sao Germano LTDA
-
-
-
-
-
Antwerp、ベルギー、2030
- ZAS Cadix
-
Bruges、ベルギー、8000
- AZ St.-Jan Brugge-Oostende AV
-
Ghent、ベルギー、9000
- UZ Gent
-
Haine Saint Paul La Louviere、ベルギー、7100
- Hopital de Jolimont
-
Kortrijk、ベルギー、8500
- Az Groeninge
-
Leuven、ベルギー、3000
- UZ Leuven
-
Roeselare、ベルギー、8800
- Algemeen Ziekenhuis Delta
-
-
-
-
-
Gdansk、ポーランド、80-214
- Klinika Hematologii i Transplantologii, UCK
-
Katowice、ポーランド、40 519
- Pratia Onkologia Katowice
-
Kielce、ポーランド、25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Lublin、ポーランド、20 090
- Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
-
Warsaw、ポーランド、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wałbrzych、ポーランド、58 309
- Specjalistyczny Szpital im dra Alfreda Sokolowskiego w Walbrzychu
-
Wroclaw、ポーランド、50 367
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Moscow、ロシア、125284
- S.P. Botkin Moscow City Clinical Hospital
-
Moscow、ロシア、125284
- S.P. Botkin Moscow City Clinical Hospital 1
-
Saint Petersburg、ロシア、191024
- Clinical Research Institute of Hematology and Transfusiology
-
-
-
-
-
Beijing、中国、100044
- Peking University People's Hospital
-
Beijing、中国、100191
- Peking University Third Hospital
-
Beijing、中国、100034
- Peking University First Hospital
-
Changchun、中国、130021
- The First Hospital of Jilin University
-
Changshashi、中国、410013
- The Third Xiangya Hospital of Central Sourth University
-
Chaoyang District、中国、100020
- Beijing Chaoyang Hospital
-
Chengdu、中国、610041
- West China Hospital Sichuan University
-
Fuzhou、中国、350001
- Fujian Meidical University Union Hospital
-
Guangzhou、中国、511363
- Sun Yat -Sen University Cancer Center
-
Hangzhou、中国、310003
- First affiliated Hospital of Zhejiang University
-
Hangzhou、中国、310003
- First affiliated Hospital of Zhejiang University 1
-
Nanjing、中国、210009
- Zhongda Hospital Southeast University
-
Nanning、中国、530021
- First Affiliated Hospital of Guangxi Medical University
-
Shanghai、中国、200032
- Shanghai Zhongshan Hospital
-
Shenyang、中国、110136
- Shengjing Hospital Of China Medical University
-
Shenzhen、中国、518036
- Peking University Shenzhen Hospital
-
Tianjin、中国、300060
- Tianjin Medical University Cancer Institute and Hospital
-
Tianjin、中国、300011
- Tianjin Medical University General Hospital
-
Xi'an、中国、710004
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Xuzhou、中国、221000
- The Affiliated Hospital of Xuzhou Medical University
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Taichung、台湾、40447
- China Medical University Hospital
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
Taoyuan、台湾、333
- Chang Gung Memorial Hospital
-
-
-
-
-
Fukuoka、日本、814-0180
- Fukuoka University Hospital
-
Gifu、日本、503-8502
- Ogaki Municipal Hospital
-
Higashiibaraki-gun、日本、311-3193
- National Hospital Organization Mito Medical Center
-
Isehara、日本、259-1193
- Tokai University Hospital
-
Kamakura-shi、日本、247-8533
- Shonan Kamakura General Hospital
-
Kashiwa、日本、277 8577
- National Cancer Center Hospital East
-
Koshigaya、日本、343-8555
- Dokkyo Medical University Saitama Medical Center
-
Kumamoto、日本、860-8556
- Kumamoto University Hospital
-
Kurume、日本、830-0011
- Kurume University Hospital
-
Matsumoto、日本、399-8701
- National Hospital Organization Matsumoto Medical Center
-
Nagoya、日本、467 8602
- Nagoya City University Hospital
-
Nishinomiya Shi、日本、663 8501
- Hyogo Medical University Hospital
-
Okayama、日本、701-1192
- National Hospital Organization Okayama Medical Center
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Sendai、日本、983-8520
- National Hospital Organization Sendai Medical Center
-
Sendai、日本、980 8574
- Tohoku University Hospital
-
Shibuya-ku、日本、150-8935
- Japanese Red Cross Medical Center
-
Shiwa-gun、日本、028-3695
- Iwate Medical University Hospital
-
Ōtake、日本、739-0696
- National Hospital Organization Hiroshima-Nishi Medical Center
-
-
-
-
-
Daegu、韓国、41944
- Kyungpook National University Hospital
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Jeollanam-do、韓国、58128
- Chonnam National University Hwasun Hospital
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Documented multiple myeloma as defined by the criteria: a. multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria, b. measurable disease at screening as defined by any of the following: 1) serum M-protein level greater than or equal to (>=) 0.5 gram per deciliter (g/dL); or 2) urine M-protein level >=200 milligrams (mg)/24 hours; or 3) serum immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory. Stable disease or progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion
- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and prior to the start of administration of study treatment
- Have clinical laboratory values within the specified range
Exclusion Criteria:
-
Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients. Additional exclusion criteria pertaining to specific study drugs include:
- A participant is not eligible to receive daratumumab subcutaneous (SC) in combination with pomalidomide and dexamethasone (DPd) as control therapy if any of the following are present: 1) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to pomalidomide, 2) Disease that is considered refractory to pomalidomide per IMWG,
- A participant is not eligible to receive daratumumab SC in combination with bortezomib and dexamethasone (DVd) as control therapy if any of the following are present: 1) Contraindications or life-threatening allergies, hypersensitivity, or intolerance to bortezomib, 2) Grade 1 peripheral neuropathy with pain or Grade >= 2 peripheral neuropathy as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0, 3) Disease that is considered refractory to bortezomib per IMWG, 4) Received a strong cytochromes P450 (CYP3A4) inducer within 5 half-lives prior to randomization
-
Received any prior B cell maturation antigen (BCMA)-directed therapy
-
Has disease that is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody per IMWG
-
Received a cumulative dose of corticosteroids equivalent to >=140 mg of prednisone within 14 days before randomization
-
Received a live, attenuated vaccine within 4 weeks before randomization
-
Plasma cell leukemia at the time of screening, Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary amyloid light chain amyloidosis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Arm A: Teclistamab-daratumumab (Tec-Dara)
Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose. Participants who are still receiving the treatment and benefiting from it may enter the long-term extension (LTE) and drug access (DA)-LTE Phases to continue their current treatment until end of the study. |
Daratumumab will be administered SC injection. Teclistamab will be administered SC injection.
他の名前:
|
|
実験的:Arm B: DPd or DVd
Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously. Participants randomized to Arm B who do not cross over to Tec-Dara may continue DPd/DVd treatment during the LTE phase. Following the completion of LTE phase, participants who crossed over to Tec-Dara during the LTE may enter the DA LTE and continue to receive study treatment with Tec Dara. Any participants still receiving DPd/DVd at the end of the LTE may not cross over to Tec-Dara and will not continue into the DA-LTE. |
Daratumumab will be administered SC injection. Pomalidomide will be administered orally. Dexamethasone will be administered orally or intravenously. Bortezomib will be administered SC injection. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠:Up to 5 years
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first. |
Up to 5 years
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response (Partial Response [PR] or Better)
時間枠:Up to 5 years
|
Overall response (PR or better) is defined as participants who have a PR or better per IMWG criteria. |
Up to 5 years
|
|
Very Good Partial Response (VGPR) or Better
時間枠:Up to 5 years
|
VGPR or better is defined as participants who achieve a VGPR or better response per IMWG criteria. |
Up to 5 years
|
|
Complete Response (CR) or Better
時間枠:Up to 5 years
|
CR or better is defined as participants who achieve a CR or better response per IMWG criteria. |
Up to 5 years
|
|
Minimal Residual Disease (MRD)-negativity
時間枠:Up to 5 years
|
MRD-negativity is defined as participants who achieve MRD negativity at a threshold of 10^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy. |
Up to 5 years
|
|
Progression Free Survival on Next-line Therapy (PFS2)
時間枠:Up to 5 years
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. |
Up to 5 years
|
|
Overall Survival (OS)
時間枠:Up to 5 years
|
OS is measured from the date of randomization to the date of the participant's death. |
Up to 5 years
|
|
Time to Next Treatment (TTNT)
時間枠:Up to 5 years
|
TTNT is defined as the interval time from randomization to the start of subsequent antimyeloma treatment. |
Up to 5 years
|
|
Duration of Response
時間枠:Up to 5 years
|
Duration of response will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG response criteria, or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Number of Participants with Adverse Events (AEs) by Severity
時間枠:Up to 5 years
|
Number of participants with AEs by Severity will be reported. |
Up to 5 years
|
|
Serum Concentration of Teclistamab
時間枠:Up to 5 years
|
Serum samples will be analyzed to determine concentrations of teclistamab using a validated, specific, and sensitive method. |
Up to 5 years
|
|
Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab and Daratumumab
時間枠:Up to 5 years
|
Number of participants with ADAs to teclistamab and daratumumab will be reported. |
Up to 5 years
|
|
Time to Worsening of Symptoms
時間枠:Up to 5 years
|
Time to worsening is measured as the interval from the date of randomization to the start date of meaningful change. |
Up to 5 years
|
|
Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30)
時間枠:Baseline up to 5 years
|
The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems. |
Baseline up to 5 years
|
|
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
時間枠:Baseline up to 5 years
|
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale. |
Baseline up to 5 years
|
|
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Measurement Information System Short Form v2.0 - Physical Function 8c (PROMIS PF 8c)
時間枠:Baseline up to 5 years
|
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. Higher overall score indicates more sleep disturbance. |
Baseline up to 5 years
|
|
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE )
時間枠:Baseline up to 6 months
|
The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact. |
Baseline up to 6 months
|
|
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
時間枠:Baseline up to 5 years
|
The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). |
Baseline up to 5 years
|
|
Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
時間枠:Baseline up to 5 years
|
The PGIS contains 2 questions on how the participant would currently rate severity of symptoms and impacts with a 7-day recall period. The response options are presented as a 5-point verbal rating scale from 1="none" to 5="very severe." |
Baseline up to 5 years
|
|
PFS in Participants with High-risk Molecular Features
時間枠:Up to 5 years
|
PFS in participants with high-risk molecular features will be reported. |
Up to 5 years
|
|
Depth of Response in Participants in High-risk Molecular Features
時間枠:Up to 5 years
|
Depth of response in participants in high-risk molecular features will be reported. |
Up to 5 years
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- CR109049
- 2020-004742-11 (EudraCT番号)
- 64007957MMY3001 (その他の識別子:Janssen Research & Development, LLC)
- 2023-503441-55-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。